Navigation Links
New study shows promise for developing new treatments for breast cancer
Date:3/14/2012

LEXINGTON, Ky. (March 14, 2012) A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early metastasis and resistance to chemotherapy and occurs at women at a younger age.

Tumor cells can exploit a cellular program that promotes cell migration and reduces adhesion between cells to spread to distant sites in the body. This cellular program, known as the epithelial-mesenchymal transition, requires large-scale cell movement during embryonic development, tissue remodeling and wound healing. Tumor cells take over this developmental program for their cell movement during invasion and metastasis.

In this EMT process, expression of a cell-to-cell adhesion molecule called E-cadherin, which functions as a "molecular glue" that binds cells to one another, needs to be downregulated in order for cells to disassociate from each other and spread throughout the body. A protein called Snail acts as a master switch in the cell's nucleus to suppress E-cadherin expression and induce EMT in the cell. However, how Snail achieves this task remains unclear. Understanding this molecular mechanism will help to develop novel agents to disrupt this EMT event for treating metastatic breast cancer.

The study, recently published online in the Journal of Clinical Investigation, identified that Snail interacted with a chromatin modifying enzyme G9a and recruited G9a to the E-cadherin promoter. This action closes the gene structure of E-cadherin and thus results in the suppression of "molecular glue" E-cadherin expression. The findings establish that the interaction of Snail with G9a is an important determinant of metastasis in triple-negative breast cancer.

"This finding has significant clinical ramification, because chemical compounds or agents that can disrupt the interaction of Snail with G9a will have a great therapeutic potential of treating triple-negative breast cancer," said UK's Peter Zhou, principal investigator for the study. "Investigators at the Markey Cancer Center are currently exploring this idea and are keen to develop drugs that can treat triple-negative breast cancer."

Triple-negative breast cancer is the worst subtype of breast cancer. This subtype of breast cancer has poor clinical outcome due to the early metastasis of tumor cells and the lack of specific drugs that target it.

"An understanding of the mechanism underlying the biology of metastasis in triple-negative breast cancer will provide novel therapeutic approaches to combat this life-threatening disease," Zhou said.


'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: